← Feed

Booth Andrew

SEC Form 4 insider
Chief Financial Officer · AbCellera Biologics Inc. ($ABCL)
1 thesis · first seen Aug 14, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$ABCLSEC Form 4bullish
Booth Andrew · Chief Financial Officer at AbCellera Biologics Inc. · 3h agono track record yet
Long 37,200 shares of ABCL
Bought 37,200 @ $10.32 avg · $383,904 · 2026-08-14

Form 4: Booth Andrew bought ABCL

Booth Andrew (Chief Financial Officer at AbCellera Biologics Inc.) reported an open-market purchase of 37,200 shares of ABCL at an average $10.32, roughly $383,904, in a Form 4 filed 2026-08-14.

Now $11.421m ago
View filing on SEC.gov →

End of results.